Asal Ebrahimian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asal Ebrahimian has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Afshin Moradi
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
8 shared publications - Amirreza Naseri
Student Research Committee Tabriz University of Medical Sciences Tabriz Iran
3 shared publications - Saeed Sadigh-Eteghad
Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications - Fereshteh Farajdokht
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Mahnaz Talebi
Neurosciences Research Center (NSRC) Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Seyed Zanyar Athari
Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
The association between depressive symptoms and sleep quality in patients with multiple sclerosis: a systematic review and meta-analysis
Multiple sclerosis (MS) is a chronic, immune-mediated disease often associated with neuropsychiatric complications, including depressive symptoms and sleep disturbances. Evidence regarding their association remains inconsistent; therefore, this systematic review and meta-analysis aimed to investigate the correlation between depressive symptoms and sleep quality in patients with MS. A systematic search was conducted across PubMed, Embase, Web of Science, and Scopus up to February 2, 2025. Cross-sectional and case-control studies which assessed sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and depressive symptoms using validated instruments were included. Two independent reviewers conducted the study selection, data extraction, and risk of bias assessment. Pooled correlation coefficients (r) were calculated using Comprehensive Meta-Analysis software (CMA). Twenty-one studies comprising 3,144 patients with MS were included. Depressive symptoms were assessed using the scales including Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS), Hamilton Depression Rating Scale (HDRS). Meta-analysis demonstrated a moderate positive correlation between PSQI and different scales of depressive symptoms (r = 0.46, 95% CI: 0.37-0.55, p < 0.01); however, heterogeneity was considerable (I² = 83.3%). The certainty of evidence was low considering the observational nature of the included studies and substantial inconsistency. Subgroup analysis of studies based on the scales of depressive symptoms showed lower heterogeneity. This review suggests a possible association between poor sleep quality and depressive symptoms in patients with MS; however, the findings should be interpreted cautiously because of the low certainty of evidence. Further well-designed prospective studies are needed to clarify the strength and direction of this relationship.
- 15 June 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessThe association between depressive symptoms and sleep quality in patients with multiple sclerosis: a systematic review and meta-analysis
Multiple sclerosis (MS) is a chronic, immune-mediated disease often associated with neuropsychiatric complications, including depressive symptoms and sleep disturbances. Evidence regarding their association remains inconsistent; therefore, this systematic review and meta-analysis aimed to investigate the correlation between depressive symptoms and sleep quality in patients with MS. A systematic search was conducted across PubMed, Embase, Web of Science, and Scopus up to February 2, 2025. Cross-sectional and case-control studies which assessed sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and depressive symptoms using validated instruments were included. Two independent reviewers conducted the study selection, data extraction, and risk of bias assessment. Pooled correlation coefficients (r) were calculated using Comprehensive Meta-Analysis software (CMA). Twenty-one studies comprising 3,144 patients with MS were included. Depressive symptoms were assessed using the scales including Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS), Hamilton Depression Rating Scale (HDRS). Meta-analysis demonstrated a moderate positive correlation between PSQI and different scales of depressive symptoms (r = 0.46, 95% CI: 0.37-0.55, p < 0.01); however, heterogeneity was considerable (I² = 83.3%). The certainty of evidence was low considering the observational nature of the included studies and substantial inconsistency. Subgroup analysis of studies based on the scales of depressive symptoms showed lower heterogeneity. This review suggests a possible association between poor sleep quality and depressive symptoms in patients with MS; however, the findings should be interpreted cautiously because of the low certainty of evidence. Further well-designed prospective studies are needed to clarify the strength and direction of this relationship.
- Open Access
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , 1530362
Transcranial Photobiomodulation Attenuates Neurogenic Inflammation and Sensory Hypersensitivity in a Nitroglycerin‐Induced Migraine Model: Toward a Nonpharmacological Therapy
Background: Migraine is a debilitating neurological condition, characterized by headache, photophobia, and heightened mechanical/thermal sensitivity. Current pharmacological therapies often lead to incomplete relief and adverse effects, necessitating the use of noninvasive alternatives. This study evaluated transcranial photobiomodulation (PBM) in a nitroglycerin (NTG)‐induced migraine model in male mice. Methods: Mice were assigned to Sham, NTG, NTG + Sumatriptan (SUMA; 600 µg/kg, s.c.), NTG + PBM, and NTG + PBM + SUMA groups. Over 9 days, NTG (5 mg/kg) was injected intraperitoneally every other day to develop an animal model of chronic migraine. The PBM protocol involved daily irradiation (810 nm) on the occipital bone of the head for 5 s over 9 days. The animals underwent behavioral testing for photophobia, mechanical allodynia, and thermal sensitivity. The trigeminal nucleus caudalis (TNC) was assessed for miR‐155 expression by real‐time PCR and protein expression of phospho‐NF‐κB, IL‐1 β , transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1), calcitonin gene–related peptide (CGRP), c‐Fos, and pituitary adenylate cyclase–activating polypeptide (PACAP) using immunoblotting. Results: Behavioral assessment revealed that PBM significantly reduced head scratching and improved exploratory activity, decreased light aversion, reversed periorbital/hindpaw mechanical allodynia, and prolonged thermal withdrawal latency compared to the NTG group. Moreover, PBM downregulated miR‐155 expression and decreased levels of inflammatory mediators and migraine‐associated neuropeptides in the TNC. Notably, combined PBM and SUMA treatment resulted in improvements in behavioral and molecular outcomes compared to either treatment alone. Conclusion: These results indicate that PBM inhibited migraine‐like behaviors and decreased the expression of numerous molecular markers that are linked to neuroinflammation and trigeminal activation in the TNC. These findings establish a foundation for additional research on transcranial PBM as a noninvasive method for modulating migraine‐related behavioral responses.
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , 1530362
Open AccessTranscranial Photobiomodulation Attenuates Neurogenic Inflammation and Sensory Hypersensitivity in a Nitroglycerin‐Induced Migraine Model: Toward a Nonpharmacological Therapy
Background: Migraine is a debilitating neurological condition, characterized by headache, photophobia, and heightened mechanical/thermal sensitivity. Current pharmacological therapies often lead to incomplete relief and adverse effects, necessitating the use of noninvasive alternatives. This study evaluated transcranial photobiomodulation (PBM) in a nitroglycerin (NTG)‐induced migraine model in male mice. Methods: Mice were assigned to Sham, NTG, NTG + Sumatriptan (SUMA; 600 µg/kg, s.c.), NTG + PBM, and NTG + PBM + SUMA groups. Over 9 days, NTG (5 mg/kg) was injected intraperitoneally every other day to develop an animal model of chronic migraine. The PBM protocol involved daily irradiation (810 nm) on the occipital bone of the head for 5 s over 9 days. The animals underwent behavioral testing for photophobia, mechanical allodynia, and thermal sensitivity. The trigeminal nucleus caudalis (TNC) was assessed for miR‐155 expression by real‐time PCR and protein expression of phospho‐NF‐κB, IL‐1 β , transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1), calcitonin gene–related peptide (CGRP), c‐Fos, and pituitary adenylate cyclase–activating polypeptide (PACAP) using immunoblotting. Results: Behavioral assessment revealed that PBM significantly reduced head scratching and improved exploratory activity, decreased light aversion, reversed periorbital/hindpaw mechanical allodynia, and prolonged thermal withdrawal latency compared to the NTG group. Moreover, PBM downregulated miR‐155 expression and decreased levels of inflammatory mediators and migraine‐associated neuropeptides in the TNC. Notably, combined PBM and SUMA treatment resulted in improvements in behavioral and molecular outcomes compared to either treatment alone. Conclusion: These results indicate that PBM inhibited migraine‐like behaviors and decreased the expression of numerous molecular markers that are linked to neuroinflammation and trigeminal activation in the TNC. These findings establish a foundation for additional research on transcranial PBM as a noninvasive method for modulating migraine‐related behavioral responses.
- Open Access
- 4 December 2025
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Restless legs syndrome as a comorbidity in amyotrophic lateral sclerosis: a systematic review and meta-analysis
Restless Legs Syndrome (RLS), characterized by an urge to move the legs, is linked to neurodegenerative diseases. Emerging evidence suggests a higher RLS p
- 4 December 2025
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessRestless legs syndrome as a comorbidity in amyotrophic lateral sclerosis: a systematic review and meta-analysis
Restless Legs Syndrome (RLS), characterized by an urge to move the legs, is linked to neurodegenerative diseases. Emerging evidence suggests a higher RLS p
- Open Access
- 13 November 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 263
Evaluation of dihydrotestosterone levels and total testosterone to dihydrotestosterone ratio with clinical symptoms and metabolic parameters in patients with polycystic ovary syndrome
Background: Polycystic ovary syndrome (PCOS) is a clinically heterogeneous endocrine disorder with lifelong health risks. Androgen excess, particularly testosterone, plays a key role in the pathophysiology of PCOS. Dihydrotestosterone (DHT) is an active metabolite derived from testosterone, and the total testosterone (TT) to DHT ratio is known as a potential marker of androgen metabolism, which can be used for evaluation of metabolic phenotype. This exploratory study aims to evaluate the association between DHT levels and TT/DHT ratio with the metabolic parameters and clinical features of PCOS patients. Methods: This cross-sectional study was conducted on 30 patients diagnosed with PCOS based on the Rotterdam 2003 criteria. Clinical, metabolic, and biochemical parameters were assessed. The association between DHT levels, TT/DHT ratio, and clinical as well as metabolic features was analyzed using ANOVA, Spearman correlation, and independent sample t-tests, with a significance threshold of p < 0.05. Results: The TT/DHT ratio was significantly lower in patients with regular menstruation compared to those with oligomenorrhea and amenorrhea ( p < 0.05). A moderate positive correlation was found between DHT levels and BMI ( r = 0.487, p < 0.05), while fasting blood sugar (FBS) was significantly correlated with the TT/DHT ratio ( r = 0.376, p < 0.05). Patients with insulin resistance had a significantly higher TT/DHT ratio compared to those without insulin resistance ( p < 0.05), whereas DHT levels did not differ significantly between these groups. Conclusion: The TT/DHT ratio could be a useful biomarker to identify PCOS patients with more severe metabolic issues.
- 13 November 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 263
Open AccessEvaluation of dihydrotestosterone levels and total testosterone to dihydrotestosterone ratio with clinical symptoms and metabolic parameters in patients with polycystic ovary syndrome
Background: Polycystic ovary syndrome (PCOS) is a clinically heterogeneous endocrine disorder with lifelong health risks. Androgen excess, particularly testosterone, plays a key role in the pathophysiology of PCOS. Dihydrotestosterone (DHT) is an active metabolite derived from testosterone, and the total testosterone (TT) to DHT ratio is known as a potential marker of androgen metabolism, which can be used for evaluation of metabolic phenotype. This exploratory study aims to evaluate the association between DHT levels and TT/DHT ratio with the metabolic parameters and clinical features of PCOS patients. Methods: This cross-sectional study was conducted on 30 patients diagnosed with PCOS based on the Rotterdam 2003 criteria. Clinical, metabolic, and biochemical parameters were assessed. The association between DHT levels, TT/DHT ratio, and clinical as well as metabolic features was analyzed using ANOVA, Spearman correlation, and independent sample t-tests, with a significance threshold of p < 0.05. Results: The TT/DHT ratio was significantly lower in patients with regular menstruation compared to those with oligomenorrhea and amenorrhea ( p < 0.05). A moderate positive correlation was found between DHT levels and BMI ( r = 0.487, p < 0.05), while fasting blood sugar (FBS) was significantly correlated with the TT/DHT ratio ( r = 0.376, p < 0.05). Patients with insulin resistance had a significantly higher TT/DHT ratio compared to those without insulin resistance ( p < 0.05), whereas DHT levels did not differ significantly between these groups. Conclusion: The TT/DHT ratio could be a useful biomarker to identify PCOS patients with more severe metabolic issues.
- Open Access
- 1 January 2025
- Published by Wiley in Stroke Research and Treatment
- Vol. 2025 (1)
Association Between TSH Level and Stroke Severity: A Cross‐Sectional Study Using the mRS
Background: Stroke is a major global health issue with numerous contributing risk factors. One of the most important risk factors of stroke is cardiovascular disease. Other risk factors include dyslipidemia, obesity, diabetes, and thyroid dysfunction which are known to increase the risk of cardiovascular disease. As dysfunction of the thyroid and its related hormones such as thyroid‐stimulating hormone (TSH) are in correlation with cardiovascular disease, which may lead to stroke, investigating the correlation between TSH levels and the severity of stroke is worth attention. Methods: This cross‐sectional study was conducted in Imam Reza Hospital in Tabriz, Iran, from March 2021 to March 2023. In this study, 204 stroke patients whose TSH levels were evaluated were included. Data on age, gender, comorbidities, TSH levels, stroke subtype, and disability severity (measured by the modified Rankin scale [mRS] before admission, during admission, at discharge, and after 3 months) were analyzed using SPSS Version 22. Results: Out of 204 patients, TSH levels of 35 (17.2%) patients were below the range (TSH < 0.39), 154 (75.5%) patients within the range (TSH: 0.39–6.19), and 15 (7.4%) patients had TSH levels above the range (TSH > 6.19). There is a weak to moderate but statistically significant correlation between mRS and TSH level during admission ( R = −0.25, p < 0.01) and at discharge ( R = −0.28, p < 0.01). However, there is a nonsignificant correlation before admission ( R = −0.10, p = 0.174) and 3 months after discharge ( R = −0.12, p = 0.137). There is not a significant difference among TSH groups comparing their age, gender, type of stroke, and CT scan findings. Conclusion: Elevated TSH levels may be associated with less severe stroke symptoms at both admission and discharge. Further studies with larger sample sizes are necessary to better understand the relationship between thyroid function and stroke.
- 1 January 2025
- Published by Wiley in Stroke Research and Treatment
- Vol. 2025 (1)
Open AccessAssociation Between TSH Level and Stroke Severity: A Cross‐Sectional Study Using the mRS
Background: Stroke is a major global health issue with numerous contributing risk factors. One of the most important risk factors of stroke is cardiovascular disease. Other risk factors include dyslipidemia, obesity, diabetes, and thyroid dysfunction which are known to increase the risk of cardiovascular disease. As dysfunction of the thyroid and its related hormones such as thyroid‐stimulating hormone (TSH) are in correlation with cardiovascular disease, which may lead to stroke, investigating the correlation between TSH levels and the severity of stroke is worth attention. Methods: This cross‐sectional study was conducted in Imam Reza Hospital in Tabriz, Iran, from March 2021 to March 2023. In this study, 204 stroke patients whose TSH levels were evaluated were included. Data on age, gender, comorbidities, TSH levels, stroke subtype, and disability severity (measured by the modified Rankin scale [mRS] before admission, during admission, at discharge, and after 3 months) were analyzed using SPSS Version 22. Results: Out of 204 patients, TSH levels of 35 (17.2%) patients were below the range (TSH < 0.39), 154 (75.5%) patients within the range (TSH: 0.39–6.19), and 15 (7.4%) patients had TSH levels above the range (TSH > 6.19). There is a weak to moderate but statistically significant correlation between mRS and TSH level during admission ( R = −0.25, p < 0.01) and at discharge ( R = −0.28, p < 0.01). However, there is a nonsignificant correlation before admission ( R = −0.10, p = 0.174) and 3 months after discharge ( R = −0.12, p = 0.137). There is not a significant difference among TSH groups comparing their age, gender, type of stroke, and CT scan findings. Conclusion: Elevated TSH levels may be associated with less severe stroke symptoms at both admission and discharge. Further studies with larger sample sizes are necessary to better understand the relationship between thyroid function and stroke.
- 7 December 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 93, 106219
Sleep quality in multiple sclerosis: A systematic review and meta-analysis based on Pittsburgh Sleep Quality Index
- 7 December 2024
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 93, 106219
Sleep quality in multiple sclerosis: A systematic review and meta-analysis based on Pittsburgh Sleep Quality Index
- Open Access
- 1 October 2024
- Published by Maad Rayan Publishing Company in Biomedicine Advances
- Vol. 1 (1) , 20-26
Investigation of the impact of iron deficiency anemia on the clinical outcome of hospitalized patients and the 6-month outcome of acute STEMI patients undergoing primary angioplasty
Background: Acute myocardial infarction (MI), particularly ST-elevation myocardial infarction (STEMI), is a severe form of acute coronary syndrome often resulting from complete coronary artery occlusion. Iron deficiency (ID) is a prevalent nutritional disorder worldwide and may influence cardiovascular outcomes, including in STEMI patients. This study aimed to assess the impact of ID on left ventricular function and clinical outcomes in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Methods: This prospective study included 257 patients with acute STEMI admitted to Shahid Madani hospital in Tabriz between October 2020 and October 2022. Patients who presented within 12 hours of chest pain onset and met the inclusion criteria were categorized into two groups based on the presence or absence of ID, defined by serum ferritin levels <100 mg/dL or transferrin saturation<20%. Comprehensive demographic, clinical, and angiographic data were collected. The primary outcomes assessed were the occurrence of major adverse cardiovascular events (MACE), thrombolysis in myocardial infarction (TIMI) flow grading, and enzymatic infarct size during hospitalization and at 6-month follow-up. Findings: ID was present in 54.4% of the patients. No significant differences were observed between the ID and non-ID groups regarding age, gender, body mass index (BMI), prevalence of comorbidities, or baseline left ventricular ejection fraction (LVEF). Additionally, the incidence of in-hospital and 6-month MACE, TIMI flow after PPCI, and enzymatic infarct size did not differ significantly between the two groups. However, serum iron, transferrin saturation, and ferritin levels were significantly lower in the ID group. Conclusion: Although ID was common among STEMI patients undergoing PPCI, it did not significantly affect in-hospital or 6-month outcomes. These findings suggest that ID may not be a crucial determinant of prognosis in STEMI patients, but further large-scale studies are needed to corroborate these results.
- 1 October 2024
- Published by Maad Rayan Publishing Company in Biomedicine Advances
- Vol. 1 (1) , 20-26
Open AccessInvestigation of the impact of iron deficiency anemia on the clinical outcome of hospitalized patients and the 6-month outcome of acute STEMI patients undergoing primary angioplasty
Background: Acute myocardial infarction (MI), particularly ST-elevation myocardial infarction (STEMI), is a severe form of acute coronary syndrome often resulting from complete coronary artery occlusion. Iron deficiency (ID) is a prevalent nutritional disorder worldwide and may influence cardiovascular outcomes, including in STEMI patients. This study aimed to assess the impact of ID on left ventricular function and clinical outcomes in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Methods: This prospective study included 257 patients with acute STEMI admitted to Shahid Madani hospital in Tabriz between October 2020 and October 2022. Patients who presented within 12 hours of chest pain onset and met the inclusion criteria were categorized into two groups based on the presence or absence of ID, defined by serum ferritin levels <100 mg/dL or transferrin saturation<20%. Comprehensive demographic, clinical, and angiographic data were collected. The primary outcomes assessed were the occurrence of major adverse cardiovascular events (MACE), thrombolysis in myocardial infarction (TIMI) flow grading, and enzymatic infarct size during hospitalization and at 6-month follow-up. Findings: ID was present in 54.4% of the patients. No significant differences were observed between the ID and non-ID groups regarding age, gender, body mass index (BMI), prevalence of comorbidities, or baseline left ventricular ejection fraction (LVEF). Additionally, the incidence of in-hospital and 6-month MACE, TIMI flow after PPCI, and enzymatic infarct size did not differ significantly between the two groups. However, serum iron, transferrin saturation, and ferritin levels were significantly lower in the ID group. Conclusion: Although ID was common among STEMI patients undergoing PPCI, it did not significantly affect in-hospital or 6-month outcomes. These findings suggest that ID may not be a crucial determinant of prognosis in STEMI patients, but further large-scale studies are needed to corroborate these results.
- 22 January 2024
- Published by Springer Nature in Inflammopharmacology
- Vol. 32 (2) , 927-944
The effects of melatonin supplementation on neurobehavioral outcomes and clinical severity in rodent models of multiple sclerosis; a systematic review and meta-analysis
Background Through the antioxidant and anti-inflammation pathways, melatonin is proposed as a safe and effective intervention in neurological diseases. This study aims to evaluate the effects of melatonin supplementation on the neurobehavioral and clinical outcomes in animal models of multiple sclerosis (MS). Methods This study was conducted following the PRISMA statement. Animal studies that reported the effects of melatonin in preclinical MS models, including the experimental autoimmune encephalomyelitis (EAE) and cuprizone model for demyelination are included in this study. A systematic search in PubMed, Web of Science, Embase, and Scopus up was conducted in April 2023. The collaborative Approach to Meta-Analysis and Review of Animal Experimental Studies (CAMARADES) critical appraisal tool was used for the quality assessment of the studies and the quantitative synthetizes were conducted using the comprehensive meta-analysis software. Results Out of 542 studies, finally 21 studies, including 14 studies in the EAE model and 7 studies of the toxic demyelination method with cuprizone were included. The route of administration was intraperitoneal in 18 studies, oral in 2 studies, and subcutaneous in 1 study. The quantitative synthesis of the EAE clinical severity scale was associated with significant differences (standardized mean difference [SDM]: − 2.52; − 3.61 to − 1.42; p value < 0.01). In subgroup analyses, the difference was statistically significant in the mouse subgroup (SMD: − 2.60; − 3.74 to − 1.46; p value < 0.01). Discussion This study encountered that melatonin may be associated with improved behavioral and cognitive outcomes of preclinical models of MS with acceptable safety profiles. Funding The research was supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number: 71005).
- 22 January 2024
- Published by Springer Nature in Inflammopharmacology
- Vol. 32 (2) , 927-944
The effects of melatonin supplementation on neurobehavioral outcomes and clinical severity in rodent models of multiple sclerosis; a systematic review and meta-analysis
Background Through the antioxidant and anti-inflammation pathways, melatonin is proposed as a safe and effective intervention in neurological diseases. This study aims to evaluate the effects of melatonin supplementation on the neurobehavioral and clinical outcomes in animal models of multiple sclerosis (MS). Methods This study was conducted following the PRISMA statement. Animal studies that reported the effects of melatonin in preclinical MS models, including the experimental autoimmune encephalomyelitis (EAE) and cuprizone model for demyelination are included in this study. A systematic search in PubMed, Web of Science, Embase, and Scopus up was conducted in April 2023. The collaborative Approach to Meta-Analysis and Review of Animal Experimental Studies (CAMARADES) critical appraisal tool was used for the quality assessment of the studies and the quantitative synthetizes were conducted using the comprehensive meta-analysis software. Results Out of 542 studies, finally 21 studies, including 14 studies in the EAE model and 7 studies of the toxic demyelination method with cuprizone were included. The route of administration was intraperitoneal in 18 studies, oral in 2 studies, and subcutaneous in 1 study. The quantitative synthesis of the EAE clinical severity scale was associated with significant differences (standardized mean difference [SDM]: − 2.52; − 3.61 to − 1.42; p value < 0.01). In subgroup analyses, the difference was statistically significant in the mouse subgroup (SMD: − 2.60; − 3.74 to − 1.46; p value < 0.01). Discussion This study encountered that melatonin may be associated with improved behavioral and cognitive outcomes of preclinical models of MS with acceptable safety profiles. Funding The research was supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number: 71005).